EPSRC Centre for Doctoral Training in Advanced Biomedical Materials

生物医学材料在过去的50年里取得了巨大的进步。历史上，它们被认为是构成简单器械（例如髋关节或具有主要组织界面的伤口敷料）基础的材料。然而，生物医学材料已经发展到现在包括智能和响应材料的发展。因此，这种材料提供关于其变化的生理环境的反馈，并且能够相应地响应和适应一系列医疗保健应用。支撑这种快速发展的两个主要领域是生物医学材料制造及其表征的进步。由新型生物医学材料产生的医疗产品及其开发策略对英国和爱尔兰至关重要。正如最近的政府白色文件和财政报告所指出的那样，人们普遍认识到，我们的人口正在迅速增长和老龄化，需要更有效但更具成本效益的医疗保健干预措施。这与世界生物材料市场的证据直接相关，估计为700亿美元（2016年），预计到2021年将增长到1490亿美元，复合年增长率为16%。为了满足这一需求，预计未来十年生物医学材料工程职业将增长63%。因此，国家需要CDT来培养跨学科的学生，并为他们提供一套全面的技能，使他们能够在这个快速发展的领域竞争。除了培训高技能的劳动力外，还将进行临床和工业主导的研究，重点是开发和翻译智能和响应性生物材料，特别关注更高的通量，更高的制造和表征再现性。因此，我们提出了一个先进的生物医学材料的CDT，以满足整个曼彻斯特大学，谢菲尔德和医疗器械研究中心（CCERAM），爱尔兰共和国（ROI）的需求。我们在生物材料创新、翻译和行业参与方面的综合实力和业绩记录使英国和ROI需求与资源、技能、行业合作和队列培训保持一致。这是由曼彻斯特和合作伙伴谢菲尔德领导的英国亨利罗伊斯研究所投资2.35亿英镑的生物医学材料轴的战略支撑。为了确定需要的关键主题领域，申请人在2016年和2017年期间与200名利益相关者领导了国家罗伊斯范围界定研讨会。代表来自临床医生，行业和学术界，并确定了国家景观战略。由此，我们确定了生物电子、纤维技术、增材制造和改进临床前表征的优先研究领域。此外，还强调需要改进生产规模和再现性。因此，该CDT将重点关注这些特定领域，培训将提供一个紧密联系的多学科生物医学材料工程师队伍，以满足这些需求。所有项目都将有临床，监管和行业参与，这将允许通过我们完善的临床试验单位轻松翻译，并将研究定位为与“曼彻斯特权力下放”所带来的机会对接，因为大曼彻斯特现在控制着长期的健康和社会保健支出，准备在2016/17年度全面下放约60亿英镑的预算，该预算将持续到CDT的整个生命周期。

Biomedical Materials have advanced dramatically over the last 50 years. Historically, they were considered as materials that formed the basis of a simple device, e.g. a hip joint or a wound dressing with a predominant tissue interface. However, biomedical materials have grown to now include the development of smart and responsive materials. Accordingly, such materials provide feedback regarding their changing physiological environment and are able to respond and adapt accordingly, for a range of healthcare applications. Two major areas underpinning this rapid development are advances in biomedical materials manufacture and their characterisation. Medical products arising from novel biomedical materials and the strategies to develop them are of great importance to the UK and Ireland. It is widely recognised that we have a rapidly growing and ageing population, with demand for more effective but also cost effective healthcare interventions, as identified in recent government White Paper and Foresight reports. This links directly to evidence of the world biomaterials market, estimated to be USD 70 billion (2016) and expected to grow to USD 149 billion by 2021 at a CAGR of 16%. To meet this demand an increase of 63% in biomedical materials engineering careers over the next decade is predicted. There is therefore a national need for a CDT to train an interdisciplinary cohort of students and provide them with a comprehensive set of skills so that they can compete in this rapidly growing field. In addition to the training of a highly skilled workforce, clinically and industrially led research will be performed that focuses on developing and translating smart and responsive biomaterials with a particular focus on higher throughput, greater reproducibility of manufacture and characterisation. We therefore propose a CDT in Advanced Biomedical Materials to address the need across The Universities of Manchester, Sheffield and The Centre for Research in Medical Devices (CÚRAM), Republic of Ireland (ROI). Our combined strength and track record in biomaterials innovation, translation and industrial engagement aligns the UK and ROI need with resource, skills, industrial collaboration and cohort training. This is underpinned strategically by the Biomedical Materials axis of the UK's £235 million investment of the Henry Royce Institute, led by Manchester and partner Sheffield. To identify key thematic areas of need the applicants led national Royce scoping workshops with 200 stakeholders through 2016 and 2017. Representation was from clinicians, industry and academia and a national landscape strategy was defined. From this we have defined priority research areas in bioelectronics, fibre technology, additive manufacturing and improved pre- clinical characterisation. In addition the need for improved manufacturing scale up and reproducibility was highlighted. Therefore, this CDT will have a focus on these specific areas, and training will provide a strongly linked multidisciplinary cohort of biomedical materials engineers to address these needs. All projects will have clinical, regulatory and industry engagement which will allow easy translation through our well established clinical trials units and positions the research well to interface with opportunities arising from 'Devolution Manchester', as Greater Manchester now controls long-term health and social care spending, ready for the full devolution of a budget of around £6 billion in 2016/17 which will continue through the CDT lifespan.